Overview

Molecure is a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first-class small molecule drug candidates that directly modulate RNA and underexplored protein targets to treat multiple incurable diseases. Molecure has an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases with a fibrotic component.
Molecure also explores DUBs and develops mRNA platform.